TESTOSTERONE CYPIONATE/ DHEA *GS* 200/10MG/ML Injectable, Packaged in a multi dose 10ML vial, as a) 5 ML Formula ID 115678; b) 10 ML Formula ID 115498, APS Pharmacy

Recall Insight

This FDA Drug action (record #D-0732-2022) was formally reported on April 6, 2022, with the manufacturer initiating the action on March 23, 2022. It is classified under Moderate severity (Class II), with a current status of Terminated. Drug Depot, Inc., dba APS Pharmacy is listed as the recalling firm, operating out of Palm Harbor, FL. Federal records indicate 620 vials units are affected.

The documented reason for this recall is: Lack of sterility assurance. Distribution data in the federal record shows the product reached: Nationwide in the USA including Puerto Rico.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 4 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.